# Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma

> **NCT06744075** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Centre Henri Becquerel** · enrollment: 108 (estimated)

## Conditions studied

- B-cell Lymphoma
- Hodgkin Lymphoma

## Interventions

- **OTHER:** Blood assessment

## Key facts

- **NCT ID:** NCT06744075
- **Lead sponsor:** Centre Henri Becquerel
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-24
- **Primary completion:** 2027-12-20
- **Final completion:** 2027-12-20
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06744075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06744075, "Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06744075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*